MacroGenics CEO granted RSUs and stock options

MacroGenics Inc. President and CEO Eric Blasius Risser reported several equity compensation moves.

Rhea-AI Filing Summary

MacroGenics Inc. President and CEO Eric Blasius Risser reported several equity compensation moves. On February 12, 2026, he received 100,000 restricted stock units and 595,000 employee stock options, each tied to future vesting and exercisability conditions described in the filing.

On February 15, 2026, he exercised 16,665 restricted stock units, receiving the same number of common shares, and then disposed of 6,433 shares at $1.71 per share to cover tax obligations. After these transactions he directly owned 77,169 common shares of MacroGenics.

Insider Trade Summary

16,665 shares exercised/converted

Exercise 5 txns

Insider Risser Eric Blasius

Role President and CEO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	16,665	$0.00	$0.00
Exercise	Common Stock	16,665	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	6,433	$1.71	$11K
Grant/Award	Restricted Stock Unit	100,000	$0.00	$0.00
Grant/Award	Employee Stock Option (right to buy)	595,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 100,000 contracts (Direct); Employee Stock Option (right to buy) — 595,000 contracts (Direct); Common Stock — 77,169 shares (Direct)

Footnotes (3)

1. F1. On February 15, 2023, the reporting person was granted 50,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis.
2. F2. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.
3. F3. 12.5% of the shares underlying the grant became exercisable one year after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did MacroGenics (MGNX) report for its CEO?

MacroGenics reported that CEO Eric Blasius Risser received new equity awards and exercised existing grants. He was granted 100,000 restricted stock units and 595,000 stock options, then exercised 16,665 RSUs and had 6,433 shares withheld to cover taxes.

How many MacroGenics (MGNX) RSUs and options were granted to the CEO?

Eric Blasius Risser received 100,000 restricted stock units and 595,000 employee stock options. The RSUs and options vest and become exercisable over time under schedules described in the footnotes, tying compensation to continued service and performance milestones.

Did the MacroGenics (MGNX) CEO buy or sell shares on the open market?

The filing shows no open-market purchase or sale. Instead, the CEO exercised 16,665 RSUs into common stock and 6,433 shares were disposed of at $1.71 per share solely to satisfy tax withholding obligations related to that equity award.

How many MacroGenics (MGNX) shares does the CEO own after these transactions?

Following the reported transactions, CEO Eric Blasius Risser directly owned 77,169 shares of MacroGenics common stock. This figure reflects the RSU conversion and the shares withheld to cover taxes, as detailed in the Form 4 ownership table.

What are the vesting terms for the MacroGenics (MGNX) RSUs granted to the CEO?

Each restricted stock unit represents a right to one MacroGenics share. The RSUs vest as to 33% of the total shares one year after the grant date, with an additional 33% vesting each year thereafter, aligning equity compensation with multi-year service.

How do the MacroGenics (MGNX) stock options granted to the CEO vest?

The employee stock options have a staged vesting schedule. According to the footnotes, 12.5% of the underlying shares become exercisable one year after the grant date, with an additional 6.25% becoming exercisable on the first day of each subsequent three-month period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 06:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Risser Eric Blasius

(Last) (First) (Middle)

9704 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/15/2026		M		16,665	A	(1)	83,602	D
Common Stock	02/15/2026		F		6,433	D	$1.71	77,169	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/15/2026		M			16,665	(1)	(1)	Common Stock	16,665	$0	0	D
Restricted Stock Unit	(2)	02/12/2026		A		100,000		(2)	(2)	Common Stock	100,000	$0	100,000	D
Employee Stock Option (right to buy)	$1.71	02/12/2026		A		595,000		(3)	02/12/2036	Common Stock	595,000	$0	595,000	D

Explanation of Responses:

1. On February 15, 2023, the reporting person was granted 50,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis.

2. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.

3. 12.5% of the shares underlying the grant became exercisable one year after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.

Remarks:

	/s/ Beth A. Smith, Attorney-in-fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.